Table 3

Determinants of patient’s out of the pocket costs assessed by Cox’s regression analyses

	Healthcare patient’s costs		Non-healthcare patient’s costs		Income loss		Total patient’s costs
	HR [95% CI]	p Value	HR [95% CI]	p Value	HR [95% CI]	p Value	HR [95% CI]	p Value
NS, not significant; BASFI, Bath Ankylosing Spondylitis Functional Index (range 0–10, higher values indicating worse function); BASDAI, Bath Ankylosing Spondylitis Disease Activity Index (range 0–10, higher values indicating higher disease activity); HRs >1 indicate higher costs.
France as opposed to the Netherlands	0.65 [0.46 to 0.91]	0.01	0.69 [0.49 to 0.99]	0.04	0.93 [0.67 to 1.37]	0.7	0.99 [0.51 to 1.41]	0.9
Belgium as opposed to the Netherlands	1.64 [1.02 to 2.63]	0.04	0.65 [0.39 to 1.07]	0.09	0.79 [0.49 to 1.26]	0.3	1.04 [0.64 to 1.72]	0.9
Belgium as opposed to France	2.65 [1.54 to 4.17]	0.0003	0.93 [0.56 to 0.55]	0.8	0.84 [0.50 to 1.39]	0.5	1.05 [0.63 to 1.75]	0.8
Gender		NS	1.47 [1.04 to 2.08]	0.03		NS		NS
Age		NS		NS		NS	1.03 [1.01 to 1.04]	0.0007
BASFI		NS	1.09 [1.02 to 1.20]	0.02	1.18 [1.09 to 1.25]	<0.0000	1.28 [1.20 to 1.37]	<0.0000
BASDAI		NS	1.09 [0.98 to 1.20]	NS		NS		NS